A new surge in infections in China amid the Delta variant and an emergency approval in the US appear to have renewed Chinese bioventure executives’ interest in developing antibody therapies against COVID-19.
The US Food and Drug Administration on 30 July revised the November 2020 emergency use authorization (EUA) for Regeneron Pharmaceuticals, Inc.’s combination antibody therapy REGEN-COV (casirivimab and imdevimab) to include COVID-19 prevention in high-risk patients aged 12 or older and weighing at least 40kg
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?